Health
FDA Approves Immunotherapy That May Allow Certain Patients with Rectal Cancer to Avoid Chemotherapy, Radiation and Surgery
Source: U.S. Food and Drug Administration (FDA)
Published:
Source summary — U.S. Food and Drug Administration (FDA)
The U.S. Food and Drug Administration today granted accelerated approval for a new use of the immunotherapy Jemperli (dostarlimab-gxly) that may allow some patients with locally advanced rectal cancer to avoid common treatments that can have a lasting impact on their daily life.
This page reports what the publisher stated. MYITEDU has not independently verified these claims.
Read the original article — U.S. Food and Drug Administration (FDA) ↗
Attribution: Source: U.S. Food and Drug Administration (fda.gov)
Share
Instagram does not support sharing links from websites. Download the card, post it from the Instagram app and paste the caption.
Report a correction
Tell us about an error in this item, its translation, date or attribution. Your contact details stay private and are used only to follow up.